Pharmacy Times^® interviewed Chad Landmon, the chair of intellectual property and FDA practice groups at Axinn, Veltrop & Harkrider, on the potential impact President-elect Joseph Biden’s cabinet nominations may have on the pharmacy field in 2021.

The changes, finalized today, are generally effective for the 2022 plan year and will potentially lower enrollee cost sharing on some of the most expensive prescription drugs.

Crizotinib is the first biomarker-driven therapy for relapsed or refractory anaplastic large cell lymphoma in children and young adults.
 

Recent surveys indicate that the proportion of the US population willing to be vaccinated for COVID-19 has fluctuated from 72% in May to 51% in September 2020.
 

The recommendations focus on dilution errors, vaccine and monoclonal antibody mix-ups, waste of doses, administering immunizations to the wrong age group, errors with scheduling the second dose, and allergic reactions.

In a statement by the APhA, Scott J. Knoer, executive vice president and CEO of APhA, noted the association’s support for this first step by the Biden administration on the road to recovery from the pandemic.

Although safety and efficacy have been proven, a few questions still remain about how long the vaccines will be effective and whether they prevent asymptomatic infection.

Participants with severe withdrawal symptoms were more likely to be younger, longtime and frequent users of cannabis, and to have worse mental health.
 

Novel program found cost effective and safe for patients with cancer managing the adverse effects of treatment. 
 

New research suggests immunosuppressants do not increase the risk of worse COVID-19 outcomes. 

 

Sources of transmission and challenges that impact the management of community-onset C. difficile.
 

In a statement released by NCPA, the association explained that the current COVID-19 vaccination rollout in the country could be accelerated by working with community pharmacists.